RBC Capital Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)

September 26, 2024 6:23 AM EDT Send to a Friend
RBC Capital analyst Luca Issi reiterated an Outperform rating and $70.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS)The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login